Originally published by our sister publication Gastroenterology & Endoscopy News
By Monica J. Smith
PHILADELPHIA—Patients with Crohn’s disease or ulcerative colitis who had achieved a clinical response to subcutaneous infliximab induction therapy in the LIBERTY trials and went on to maintenance/extension therapy showed no meaningful differences in efficacy outcomes regardless of whether induction infliximab was given as monotherapy or in combination with immunosuppressants,